DSpace Repository

Calreticulin Mutations in Philadelphia Chromosome Negative Myeloproliferative Neoplasms

Show simple item record

dc.contributor.author Gulbay, Gonca
dc.contributor.author Bar, Harika Gozukara
dc.contributor.author Yesilada, Elif
dc.contributor.author Erkurt, Mehmet Ali
dc.date.accessioned 2024-03-15T12:17:09Z
dc.date.available 2024-03-15T12:17:09Z
dc.date.issued 2022
dc.identifier.citation Gulbay, G., Bar, HG., Yesilada, E., Erkurt, MA. (2022). Calreticulin Mutations in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. UHOD-Uluslar. Hematol.-Onkol. De., 32(2), 75-80. https://doi.org/10.4999/uhod.225925 en_US
dc.identifier.issn 1306-133X
dc.identifier.uri http://dx.doi.org/10.4999/uhod.225925
dc.identifier.uri https://www.webofscience.com/wos/woscc/full-record/WOS:000798190600002
dc.identifier.uri http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4682
dc.description WoS Categories: Oncology en_US
dc.description Web of Science Index: Science Citation Index Expanded (SCI-EXPANDED) en_US
dc.description Research Areas: Oncology en_US
dc.description.abstract Calreticulin (CALR) is a multifunctional protein. CALR gene mutations are one of the driver mutations in cases with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The aim of this study is to comprehend the functional relationship of CALR type1 and type2 mutations in the pathogenesis of Phi-ladelphia Chromosome Negative Myeloproliferative Neop-lasms (MPNs) by emphasizing the incidence, biological and clinical features of CALR mutations in Janus Kinase2 (JAK2) V617F mutation negative and thrombopoietin receptor gene (MPL) mutation negative ET and PMF cases, and to determine their effect on the disease phenotype. The laboratory results of cases analyzed with essential throm-bocythemia and primary myelofibrosis were analyzed retros-pectively. In our study of the ET cases, 18.4% CALR exon9 mutation car-ried, 5.1% a thrombopoietin receptor gene (MPL) mutation, and 57.1% JAK2 V617F mutation. 19.4% of our cases do not carry any of these three mutations. Our ET patients with CALR muta-tion positive, 61.1% have type1, 27.8% have type2 and 11.1% have mutations other than type1 and type2. In our study of the PMF cases, 27.7% CALR exon9 mutation carried, 3.6% a MPL mutation, and 47% JAK2 V617F muta-tion. 21.7% cases are triple negative. Our PMF patients with CALR mutation positive, 69.6% have type1, 30.4% have type2 mutations. CALR mutations are a new and important molecular marker for Philadelphia chromosome negative myeloproliferative neoplasm cases. Longer follow-up and larger case populations are required to investigate the effects of clinical and laboratory pa-rameters of diseases. en_US
dc.language.iso eng en_US
dc.publisher AKAD DOKTORLAR YAYINEVI-HILAL CANKAYA en_US
dc.relation.isversionof 10.4999/uhod.225925 en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Calreticulin gene, Mutation, Philadelphia chromosome negative myeloproliferative neoplasm en_US
dc.subject ESSENTIAL THROMBOCYTHEMIA, PRIMARY MYELOFIBROSIS, DRIVER MUTATIONS, CALR MUTATIONS, GENE, JAK2(V617F), CHINESE, JAK2, MPL en_US
dc.title Calreticulin Mutations in Philadelphia Chromosome Negative Myeloproliferative Neoplasms en_US
dc.type article en_US
dc.relation.journal UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI en_US
dc.contributor.department Ordu Üniversitesi en_US
dc.contributor.authorID 0000-0002-3285-417X en_US
dc.contributor.authorID 0000-0003-1208-4072 en_US
dc.identifier.volume 32 en_US
dc.identifier.issue 2 en_US
dc.identifier.startpage 75 en_US
dc.identifier.endpage 80 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account